[an error occurred while processing this directive] | [an error occurred while processing this directive]
Clinical characteristics and prognostic analysis of young patients with stage IB-IIA cervical cancer
Zhang Gongyi,Zhang Rong,Zeng Jing, Lei Chengzhi, Wu Lingying
Department of Gynecology Oncology,Cancer Hospital,Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100021,China Corresponding author;Zhang Rong,Email:super0078888@sina.com
Abstract Objective To investigate the clinicopathological features, survival, and the impact of postoperative adjuvant radiotherapy on the ovarian function in patients less than or equal to 35 years of age with stage IB-IIA cervical cancer. Methods One hundred and eighty-six patients who were admitted to our hospital from 2000 to 2011 were retrospectively analyzed. An equal number of patients older than 35 years of age with cervical cancer within the same period were used as stage-marched controls. The Kaplan-Meier method was used to calculate the survival rates, and the log-rank test was used for pairwise comparison and univariate prognostic analyses. The Cox proportional hazards model was used for multivariate prognostic analyses. Results The patients less than or equal to 35 years of age had a significantly higher incidence of non-squamous carcinoma but significantly lower incidence rates of deep stromal invasion and lymph-vascular space invasion (LVSI) compared with the control group (P=0.000;P=0.008;P=0.000). Though young patients had significantly higher 5-year disease-free survival (DFS) and overall survival (OS) rates than the control group (93.7% vs. 84.5%, P=0.005;96.1% vs. 89.5%, P=0.033), age was not an independent prognostic factor (P=0.202;P=0.950). Among patients less than or equal to 35 years of age, lymph node metastasis and LVSI were independent prognostic factors for DFS (P=0.000;P=0.000), while LVSI and initial tumor size were independent prognostic factors for OS (P=0.000;P=0.000). There was no significant difference in the incidence of normal ovarian function between young patients treated withand without adjuvant radiotherapy after ovarian transposition (63% vs. 73%, P=0.422). Conclusions Patients less than or equal to 35 years of age with stage IB-IIA cervical cancer have a better prognosis than the control group. However, age is not an independent prognostic factor. Postoperative adjuvant radiotherapy will not impair the function of transposed ovaries.
Zhang Gongyi,Zhang Rong,Zeng Jing et al. Clinical characteristics and prognostic analysis of young patients with stage IB-IIA cervical cancer[J]. Chinese Journal of Radiation Oncology, 2015, 24(3): 262-266.
Zhang Gongyi,Zhang Rong,Zeng Jing et al. Clinical characteristics and prognostic analysis of young patients with stage IB-IIA cervical cancer[J]. Chinese Journal of Radiation Oncology, 2015, 24(3): 262-266.
[1] Foley G, Alston R, Geraci M, et al. Increasing rates of cervical cancer in young women in England:an analysis of national data 1982-2006[J]. Br J Cancer,2011,105(1):177-184.DOI:10.1038/bjc.2011.196. [2] 章文华,白萍,吴令英,等.35岁以下妇女宫颈癌[J].中国肿瘤临床与康复,1999,6(6):39-43. [3] 马珂,刘桐宇,黄伟萍,等.手术及术后化疗治疗有复发中危和高危因素的ⅠB-ⅡA期宫颈癌68例疗效分析[J].实用妇产科杂志,2012,28(11):923-927.DOI:10.3969/j.issn.1003-6946.2012.11.011. [4] 张乃怿,高雨农,燕鑫,等.具复发危险因素的ⅠB1-ⅡA期宫颈癌术后辅助化疗的疗效和安全性评价[J].实用妇产科杂志,2014,30(1):21-25. [5] 刘兰芳,孙海燕.831例35岁以下妇女宫颈癌的临床病例特点和预后[J].中国癌症杂志,2008,18(4):298-301.DOI:10.3969/j.issn.1007-3639.2008.04.014. [6] Brewster WR, Disaia PJ, Monk BJ, et al. Young age as a prognostic factor in cervical cancer:Results of a population-based study[J]. Am J Obstet Gynecol,1999,180(6 Pt 1):1464-1467. [7] Lou HY, Juang CM, Chen YJ, et al. Aggressive characteristics of cervical cancer in young women in Taiwan[J].Int J Gynaecol Obstet,2009,107(3):220-223.DOI:10.1016/j.ijgo.2009.07.029. [8] Castanon A, Leung VMW, Landy R, et al. Charatoristics and screening history of women diagnosed with cervical cancer aged 20-29 years[J]. Br J Cancer,2013,109(1):35-41.DOI:10.1038/bjc.2013.322. [9] Lavazzo C, Darlas FM, Gkegkes LD, et al. The role of robotics in ovarian transposition[J]. Acta Inform Med,2013,21(2):135-137.DOI:10.5455/aim.2013.21.135-137. [10] Zhao YB, Wang JH, Chen XX, et al. Values of three different preoperative regimens in comprehensive treatment for young patients with stage Ⅰb2 cervical cancer[J]. Asian Pacific J Cancer Prev,2012,13(4):1487-1489. [11] Gubbala K, Laios A, Gallos L, et al. Outcomes of ovarian transposition in gynaecological cancers:a systematic review and meta-analysis[J]. J Ovarian Res,2014,7(1):69-79.DOI:10.1186/1757-2215-7-69. [12] Kastritis E, Bamias A, Bozas G, et al. The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapy[J]. Gynecol Oncol,2007,104(2):372-376.
2015, Vol. 24 
